Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer Schering Will Build $129 Million Beijing R&D Center

publication date: Feb 12, 2009

Bayer Schering Pharma of Germany will invest $129 million to build a global R&D center located in Beijing. The investment will take place over five years. For Bayer Schering, China is the third largest market, and the company already has already located R&D centers in the US and Europe, its two markets that are larger than China. The Beijing center will be very mindful of the clinical profile and medical needs of Asian patients, though the center is not exclusively devoted to the Asian market. More details...

Stock Symbol: (Frankfurt: SCH)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital